<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337996</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH_2020_6</org_study_id>
    <nct_id>NCT04337996</nct_id>
  </id_info>
  <brief_title>Dynamic Evaluation of COVID-19 Diagnostic Tests</brief_title>
  <acronym>TRODVID-19</acronym>
  <official_title>Dynamic Evaluation of COVID-19 Diagnostic Tests</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tourcoing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tourcoing Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rapid antigenic tests are not yet used in real life. Their contribution in the diagnostic
      strategy based on the gold standard including anamnesis, thoracic CT and PCR has not been
      evaluated.

      We propose to compare to the Gold-Standard defined above, the combination of an SARS-Cov-2
      antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional study comparing gold standard anamnesis, thoracic CT and PCR versus
      SARS-Cov-2 antigen, anamnesis and thoracic CT for the diagnosis of COVID-19 infection.

      Patients will be sampled for the tests at Day 1 and then monitored for symptoms and clinical
      data and additional test at Day 21.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of patients classified as COVID-19 positive according to the 2 strategies</measure>
    <time_frame>day 1</time_frame>
    <description>Comparison of the Gold-Standard PCR, anamnesis, thoracic CT scan versus SARS-Cov-2 antigen, anamnesis and thoracic CT scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive or negative Covid-19 test</measure>
    <time_frame>day 1</time_frame>
    <description>Number of diagnoses invalidated by the antigen + CT scan alone without the contribution of PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive or negative character of the antibodies test</measure>
    <time_frame>day 1</time_frame>
    <description>Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive or negative character of the antibodies test</measure>
    <time_frame>day 21</time_frame>
    <description>Comparison of the proportion of patients with positive serology for SARS-Cov2 to the proportion of patients who were classified as COVID-19 at the time of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters</measure>
    <time_frame>day 1</time_frame>
    <description>Evolution of biological parameters as a function of time IgM IgA and IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters</measure>
    <time_frame>Day 21</time_frame>
    <description>Evolution of biological parameters as a function of time IgM IgA and IgG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>medical-economic comparison</measure>
    <time_frame>day 1</time_frame>
    <description>medical-economic comparison of the first-line use of the antigenic test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients whose diagnosis of SARS-Cov-2 infection was made on the Gold-Standard: combined history/clinical examination, PCR and CT scan and requiring hospitalization at Tourcoing Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COVID-19 diagnostic test</intervention_name>
    <description>COVID-19 diagnostic tests performed at day 1 (antigen in blood serum, SARS-Cov2 PCR, antibodies in blood serum) COVID-19 diagnostic test performed at day 21 (antibodies in blood serum)</description>
    <arm_group_label>experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic patient with confirmed Gold-Standard SARS-CoV-2 (COVID-19) infection

          -  Presenting at least one criterion for hospitalization:

               -  Respiratory failure and oxygenation

               -  Circulatory failure (systolic BP &lt; 90 mmHg)

               -  Neurological failure (confusion, drowsiness, altered consciousness)

               -  Polypathological terrain and co-morbidities (chronic respiratory failure, heart
                  failure or cardiovascular pathology, renal failure, diabetes, immunosuppression,
                  obesity, cirrhosis)

          -  Eligible for different sampling methods

          -  Beneficiary of a social insurance scheme or entitled person

        Exclusion Criteria:

          -  Gold Standard not in favour of SARS-Cov-2 infection (COVID 19)

          -  Minor patient

          -  Refusal to participate

          -  Patient under guardianship

          -  Patient under guardianship

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre PATOZ, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barthelemy LAFONDESMURS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Tourcoing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre PATOZ, PharmD</last_name>
    <phone>0320694540</phone>
    <email>ppatoz@ch-tourcoing.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solange TREHOUX, PhD</last_name>
    <phone>0320694280</phone>
    <email>strehoux@ch-tourcoing.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre PATOZ, PharmD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

